Showing results (91-100 of 182) with videos related to
Sort By:
Pageof 19
Breast Cancer Research and Treatment|December 27, 2011
A phase II study of lapatinib and bevacizumab as treatment for HER2-overexpressing metastatic breast cancerHope S Rugo, A Jo Chien, Sandra X Franco, et al.Breast Cancer Research and Treatment|May 19, 2022
Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature reviewEdith A Perez, Chau Dang, Caleb Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 12, 2011
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi, Alison Stopeck, Hannah Linden, et al.JAMA|April 13, 2006
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancerDonald A Berry, Constance Cirrincione, I Craig Henderson, et al.Clinical Breast Cancer|January 5, 2016
Biomarkers That Predict Sensitivity to Heat Shock Protein 90 InhibitorsKomal Jhaveri, Sarat Chandarlapaty, Neil Iyengar, et al.Journal of Geriatric Oncology|January 30, 2014
A planned, prospective comparison of short-term quality of life outcomes among older patients with breast cancer treated with standard chemotherapy in a randomized clinical trial vs. an observational study: CALGB #49907 and #369901Jeanne S Mandelblatt, Solomon B Makgoeng, Gheorghe Luta, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 30, 2008
Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840--Cancer and Leukemia Group BBlase N Polite, Constance Cirrincione, Gini F Fleming, et al.Breast Cancer Research : BCR|August 3, 2017
A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancerKomal Jhaveri, Rui Wang, Eleonora Teplinsky, et al.Breast Cancer Research and Treatment|October 6, 2016
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)Mehra Golshan, Constance T Cirrincione, William M Sikov, et al.Annals of Surgical Oncology|November 7, 2015
Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020)Faina Nakhlis, Lauren Gilmore, Rebecca Gelman, et al.Pageof 19